Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics.
van den Hoogen LL, Verheul MK, Vos ERA, van Hagen CCE, van Boven M, Wong D, Wijmenga-Monsuur AJ, Smits G, Kuijer M, van Rooijen D, Bogaard-van Maurik M, Zutt I, van Vliet J, Wolf J, van der Klis FRM, de Melker HE, van Binnendijk RS, den Hartog G. van den Hoogen LL, et al. Among authors: kuijer m. Sci Rep. 2022 Apr 8;12(1):5935. doi: 10.1038/s41598-022-10020-6. Sci Rep. 2022. PMID: 35396570 Free PMC article.
Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
van den Hoogen LL, Smits G, van Hagen CCE, Wong D, Vos ERA, van Boven M, de Melker HE, van Vliet J, Kuijer M, Woudstra L, Wijmenga-Monsuur AJ, GeurtsvanKessel CH, Stoof SP, Reukers D, Wijsman LA, Meijer A, Reusken CBEM, Rots NY, van der Klis FRM, van Binnendijk RS, den Hartog G. van den Hoogen LL, et al. Among authors: kuijer m. Vaccine. 2022 Apr 1;40(15):2251-2257. doi: 10.1016/j.vaccine.2022.03.009. Epub 2022 Mar 9. Vaccine. 2022. PMID: 35287986 Free PMC article.
Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands.
van den Hoogen LL, Boer M, Postema A, de Rond L, de Zeeuw-Brouwer ML, Pronk I, Wijmenga-Monsuur AJ, Bijvank E, Kruiper C, Beckers L, Maurik MB, Zutt I, van Vliet J, van Bergen R, Kuijer M, Smits G, Verschuren WMM, Picavet HSJ, van der Klis FRM, den Hartog G, van Binnendijk RS, Buisman AM. van den Hoogen LL, et al. Among authors: kuijer m. Vaccines (Basel). 2022 Sep 6;10(9):1480. doi: 10.3390/vaccines10091480. Vaccines (Basel). 2022. PMID: 36146557 Free PMC article.
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
Kho MML, Messchendorp AL, Frölke SC, Imhof C, Koomen VJ, Malahe SRK, Vart P, Geers D, de Vries RD, GeurtsvanKessel CH, Baan CC, van der Molen RG, Diavatopoulos DA, Remmerswaal EBM, van Baarle D, van Binnendijk R, den Hartog G, de Vries APJ, Gansevoort RT, Bemelman FJ, Reinders MEJ, Sanders JF, Hilbrands LB; RECOVAC collaborators. Kho MML, et al. Lancet Infect Dis. 2023 Mar;23(3):307-319. doi: 10.1016/S1473-3099(22)00650-8. Epub 2022 Oct 27. Lancet Infect Dis. 2023. PMID: 36354032 Free PMC article. Clinical Trial.
Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.
Roozen GVT, Prins MLM, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, Janse JJ, Kruithof AC, Feltkamp MCW, Kuijer M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Roozen GVT, et al. Among authors: kuijer m. Ann Intern Med. 2022 Dec;175(12):1771-1774. doi: 10.7326/M22-2089. Epub 2022 Oct 25. Ann Intern Med. 2022. PMID: 36279543 Free PMC article. No abstract available.
Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial.
Barug D, Berbers GAM, van Houten MA, Kuijer M, Pronk I, Knol MJ, Sanders EAM, Rots NY. Barug D, et al. Among authors: kuijer m. Vaccine. 2020 Jun 15;38(29):4632-4639. doi: 10.1016/j.vaccine.2020.04.001. Epub 2020 May 21. Vaccine. 2020. PMID: 32448624 Clinical Trial.
Protective mucosal SARS-CoV-2 antibodies in the majority of the general population in the Netherlands.
Verheul MK, Kaczorowska J, Hofstee MI, Schepp RM, Smits GP, Wessels Beljaars D, Kuijer M, Schuin W, Middelhof I, Wong D, van Hagen CCE, Vos ERA, Nicolaie MA, de Melker HE, van Binnendijk RS, van der Klis FRM, den Hartog G. Verheul MK, et al. Among authors: kuijer m. Mucosal Immunol. 2024 Mar 27:S1933-0219(24)00027-8. doi: 10.1016/j.mucimm.2024.03.008. Online ahead of print. Mucosal Immunol. 2024. PMID: 38553008 Free article.
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Roozen GVT, Prins MLM, Prins C, Janse JJ, de Gruyter HLM, Pothast CR, Huisman W, Koopman JPR, Lamers OAC, Kuijer M, Myeni SK, van Binnendijk RS, Hartog GD, Heemskerk MHM, Jochems SP, Feltkamp MCW, Kikkert M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Roozen GVT, et al. Among authors: kuijer m. Clin Microbiol Infect. 2024 Mar 28:S1198-743X(24)00159-9. doi: 10.1016/j.cmi.2024.03.028. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38552793 Free article.
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial.
Prins MLM, Roozen GVT, Pothast CR, Huisman W, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, Janse JJ, Lamers OAC, Koopman JPR, Kruithof AC, Kamerling IMC, Dijkland RC, de Kroon AC, Azimi S, Feltkamp MCW, Kuijer M, Jochems SP, Heemskerk MHM, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Prins MLM, et al. Among authors: kuijer m. NPJ Vaccines. 2024 Jan 2;9(1):1. doi: 10.1038/s41541-023-00785-w. NPJ Vaccines. 2024. PMID: 38167735 Free PMC article.
20 results